JP5798916B2 - Ｈｍｇｃｒタンパク質に関係する処置予測 - Google Patents

Ｈｍｇｃｒタンパク質に関係する処置予測 Download PDF

Info

Publication number
JP5798916B2
JP5798916B2 JP2011509434A JP2011509434A JP5798916B2 JP 5798916 B2 JP5798916 B2 JP 5798916B2 JP 2011509434 A JP2011509434 A JP 2011509434A JP 2011509434 A JP2011509434 A JP 2011509434A JP 5798916 B2 JP5798916 B2 JP 5798916B2
Authority
JP
Japan
Prior art keywords
treatment
hmgcr
sample
breast cancer
endocrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011509434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525105A (ja
JP2011525105A5 (zh
Inventor
マティアス・ウーレン
フレデリック・ポンテン
カリン・イルストレム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Antibodies AB
Original Assignee
Atlas Antibodies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Antibodies AB filed Critical Atlas Antibodies AB
Publication of JP2011525105A publication Critical patent/JP2011525105A/ja
Publication of JP2011525105A5 publication Critical patent/JP2011525105A5/ja
Application granted granted Critical
Publication of JP5798916B2 publication Critical patent/JP5798916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2011509434A 2008-05-16 2009-01-30 Ｈｍｇｃｒタンパク質に関係する処置予測 Expired - Fee Related JP5798916B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP2008/056071 2008-05-16
EPEP2008/056071 2008-05-16
PCT/EP2008/056071 WO2009138130A1 (en) 2008-05-16 2008-05-16 Breast cancer prognostics
PCT/SE2009/000066 WO2009139681A1 (en) 2008-05-16 2009-01-30 Treatment prediction involving hmgcr protei

Publications (3)

Publication Number Publication Date
JP2011525105A JP2011525105A (ja) 2011-09-15
JP2011525105A5 JP2011525105A5 (zh) 2012-03-15
JP5798916B2 true JP5798916B2 (ja) 2015-10-21

Family

ID=39777087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509434A Expired - Fee Related JP5798916B2 (ja) 2008-05-16 2009-01-30 Ｈｍｇｃｒタンパク質に関係する処置予測

Country Status (6)

Country Link
US (2) US20110144198A1 (zh)
JP (1) JP5798916B2 (zh)
CN (1) CN102089442B (zh)
AU (1) AU2009246994B2 (zh)
CA (1) CA2722411A1 (zh)
WO (2) WO2009138130A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795070C (en) * 2010-04-16 2020-04-28 The Johns Hopkins University Compositions and methods for characterizing a myopathy
US8725539B2 (en) 2010-09-07 2014-05-13 Premier Health Care Services Inc. Systems and methods for providing a continuum of care

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
WO2003018833A2 (en) * 2001-08-29 2003-03-06 Mcgill University 3-hydroxymethylglutaryl coenzyme a reductase and diagnosis and prognostication of dementia
WO2004097030A2 (en) * 2003-04-28 2004-11-11 Bristol-Myers Squibb Company Prognostic breast cancer biomarkers
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
JP5089993B2 (ja) * 2004-02-20 2012-12-05 ベリデックス・エルエルシー 乳癌の予後診断
US20090305258A1 (en) * 2006-02-17 2009-12-10 Paolo La Colla Methods for the diagnosis of proliferative and/or conformational diseases
US20090291920A1 (en) * 2006-04-18 2009-11-26 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment
WO2008019375A2 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures

Also Published As

Publication number Publication date
WO2009138130A1 (en) 2009-11-19
CA2722411A1 (en) 2009-11-19
US20110142828A1 (en) 2011-06-16
AU2009246994A1 (en) 2009-11-19
JP2011525105A (ja) 2011-09-15
WO2009139681A1 (en) 2009-11-19
US20110144198A1 (en) 2011-06-16
WO2009139681A8 (en) 2013-11-21
US8945832B2 (en) 2015-02-03
CN102089442B (zh) 2015-03-11
AU2009246994B2 (en) 2015-02-05
CN102089442A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
JP5689133B2 (ja) 結腸直腸癌におけるｐｏｄｘｌタンパク質
JP5767116B2 (ja) 白金に基づく治療に対する応答の予測
EP2318841B1 (en) Anln protein as an endocrine treatment predictive factor
EP2288721B1 (en) Treatment prediction involving hmgcr protein
US20110003854A1 (en) Breast cancer treatment and treatment prediction
AU2009213167B2 (en) RBM3 as a marker for breast cancer prognosis
JP5798916B2 (ja) Ｈｍｇｃｒタンパク質に関係する処置予測
WO2010086400A1 (en) Combination treatment of breast cancer
WO2010136560A1 (en) Means and methods for ovarian cancer prognosis

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141209

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150824

R150 Certificate of patent or registration of utility model

Ref document number: 5798916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees